#wegovy

What the Ozempic, Wegovy, Mounjaro and Zepbound labels actually say about the fridge, the counter, a hot car, a freezer, and an airport checkpoint. Each answer is in the first sentence, because you are probably reading this in a hurry.

Clinical trials show 14.9-20.7% body weight loss with semaglutide depending on dose. Standard Wegovy (2.4mg): 14.9-17% over 68 weeks. Wegovy HD (7.2mg, FDA-approved March 2026): 20.7% over 72 weeks. Month-by-month breakdown from the STEP trials.

Updated July 2026: Tirzepatide produces 20.2% weight loss vs semaglutide's 13.7% in the SURMOUNT-5 head-to-head trial (NEJM 2024): a 47% greater relative reduction confirmed by 2026 systematic meta-analyses. Tirzepatide activates GLP-1 + GIP dual receptors; semaglutide activates GLP-1 only. Full cost and side-effect comparison.

Updated August 2026: SURMOUNT-5 head-to-head trial (NEJM): Zepbound 20.2% vs Wegovy 13.7% weight loss at 72 weeks. Wegovy HD (7.2mg, FDA-approved March 2026) closes the gap at 20.7%. NovoCare lists the Wegovy pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 for HD) and pill from $149/mo, prescription required and dose-dependent; LillyDirect lists Zepbound from $299/mo with higher-dose pricing. Both may be as low as $25/mo for eligible commercially insured patients using a savings card.

How much do GLP-1 medications cost in 2026? Wegovy, Zepbound, Ozempic, Mounjaro & Foundayo range from $25 to $1,350/month. With insurance + savings card: $25/mo. Without insurance: $146/mo compounded sema (Yucca Health), $149/mo Foundayo pill, $299 to 449/mo brand injectable (LillyDirect, NovoCare). Medicare: $50/mo, live as of July 2026. Prices verified July 2026 across 53 providers.

Updated July 2026: Medicare Part D now covers Foundayo, Wegovy, and Zepbound for weight loss (live since July 1, 2026) via the Medicare GLP-1 Bridge program. Flat $50/month copay. About 3.8 million Part D enrollees are eligible (KFF, June 2026). Both oral pills (Foundayo and Wegovy tablet) are covered. Runs through Dec 31, 2027 (BALANCE Model Part D launch delayed indefinitely as of April 2026; Bridge extended to fill the gap).

Medicare GLP-1 coverage is NOW LIVE as of July 1, 2026. Here's who qualifies for the $50/month Bridge program, how to get prior auth, and whether the Bridge beats cash-pay (our 54-provider price audit).

Verified August 14, 2026: Ozempic and Wegovy are both semaglutide from Novo Nordisk. Ozempic ($1,027.51/mo list) is approved for type 2 diabetes at max 2mg. Wegovy ($1,349/mo list) is approved for weight loss at max 2.4mg (or 7.2mg HD). NovoCare lists each pen at $199/mo for the first two low-dose fills; Wegovy then costs $349/mo at standard strengths ($399 HD), while Ozempic costs $349/mo at 0.25-1mg or $499/mo at 2mg. Pills start at $149/mo and are dose-dependent.

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both FDA-approved only for type 2 diabetes, neither is approved for weight loss (that's their sister brands, Zepbound and Wegovy). In the first head-to-head trial, SURMOUNT-5, tirzepatide beat semaglutide for weight loss (−20.2% vs −13.7% over 72 weeks), and in SURPASS-2 tirzepatide cut A1C more. But Ozempic's semaglutide has the SELECT cardiovascular outcome data Mounjaro doesn't. Here's the data-driven breakdown, plus the cheaper cash-pay paths if your insurance says no.

GLP-1 medications like Ozempic and Wegovy can help PCOS because the syndrome is driven by insulin resistance, and these drugs improve insulin sensitivity, drive weight loss, and in trials restored menstrual regularity and raised natural-pregnancy rates. But here is the catch almost no one explains: PCOS by itself is NOT an FDA-approved reason to prescribe any GLP-1, so insurance and brand savings cards hinge on your BMI and comorbidities, not your PCOS diagnosis. This guide covers the trial signal, why insurance denies PCOS-only requests, the BMI rules behind savings cards, and the cheaper cash-pay paths if you do not qualify.

FDA resolved the semaglutide shortage on February 21, 2025 and ended temporary shortage-based enforcement discretion on April 22 for 503A pharmacies and May 22 for 503B facilities. This guide separates those dates from FDA's pending 503B bulk-list proposal and compares paths to discuss with a prescriber.

Updated June 11, 2026: CMS released the official prior authorization request form (cms.gov/glp-1-bridge.pdf, June 8) revealing a key eligibility nuance, beneficiaries with OSA, MASH, T2D, or established CVD are NOT eligible for the Bridge (they route through regular Part D instead). The Bridge is for weight-management-only patients. Four drugs covered at a $50/month flat copay: Foundayo, Wegovy injection, Wegovy oral tablet, and Zepbound KwikPen. Prior auth via Humana/LI NET; requests not processed before July 1. Complete enrollment guide.

FDA-approved GLP-1 receptor agonists for weight loss, 2026 guide. Eligibility: BMI 30+ (or 27+ with comorbidity). Semaglutide produces 14.9% weight loss (STEP-1), tirzepatide 20.9% (SURMOUNT-1). Cost: $25-$349/mo via telehealth. Complete 5-step prescription process with verified provider pricing. Options: Foundayo (orforglipron), oral Wegovy, Zepbound, and injectable semaglutide.

Verified August 2026: Oral Wegovy (25mg daily pill) produced 16.6% weight loss in OASIS vs 14.9% for injectable Wegovy (2.4mg weekly) in STEP-1. NovoCare lists the pill from $149/mo and pen from $199/mo, prescription required and dose-dependent. Full cross-trial comparison.

Verified July 2026: The 7 worst foods on Ozempic, Wegovy, Zepbound, fried food, sugary drinks, red meat portions, raw cruciferous veg, carbonated beverages, alcohol, high-fiber bars. GLP-1s slow gastric emptying 25-40%, triggering nausea in 44% of patients. Full list with alternatives.

Verified July 2026: 44% of Wegovy patients report nausea, 30% diarrhea, 24% vomiting in STEP-1 trial. Only 7% discontinued for side effects. Tirzepatide (Zepbound) is more tolerable: 24-33% nausea, 7-13% vomiting per SURMOUNT-1. Full management guide with red flags.

Two of the biggest telehealth platforms now offer branded Wegovy and GLP-1 programs. We compare Ro and Hims on pricing, medications, insurance, clinical support, and what actually changed after the Novo Nordisk lawsuit.